StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
14
Publishing Date
2023 - 12 - 01
1
2023 - 10 - 26
1
2022 - 10 - 04
1
2022 - 03 - 30
1
2022 - 03 - 29
2
2022 - 03 - 23
1
2022 - 02 - 14
1
2022 - 01 - 12
1
2021 - 09 - 29
1
2021 - 08 - 30
1
2021 - 08 - 04
1
2021 - 04 - 01
1
2021 - 03 - 31
1
Sector
Communications
1
Health technology
14
Tags
Acquisition
9
Active
10
Antiviral
10
Application
24
Approval
31
Authorization
14
Breast
12
Cancer
66
Candidate
16
Children
18
Clinical-trials-phase-ii
9
Clinical-trials-phase-iii
15
Collaboration
21
Comirnaty®
10
Conference
18
Covid
58
Covid-19
41
Disease
28
Drug
54
Earnings
20
Ema
10
Emergency use authorization
10
Europe
13
Events
12
Expected
10
Fda
74
Fda-approvals
14
Financial
19
Global
56
Growth
29
Hiv
15
Hormone
10
License
19
Market
100
Merge
15
N/a
432
Order
15
People
24
Pharm-country
33
Pharmaceutical
17
Phase 2
12
Phase 3
21
Positive
45
Potential
11
Product-news
10
Regulatory
12
Report
49
Research
51
Respiratory
10
Results
62
Risk
16
Study
20
Therapeutics
40
Therapy
29
Topline
14
Treatment
73
Trial
47
Ulcerative colitis
12
Update
14
Vaccine
106
Entities
89bio, inc.
3
Abbvie inc.
8
Acasti pharma, inc.
6
Acer therapeutics inc.
3
Aclaris therapeutics, inc.
3
Acumen pharmaceuticals inc
3
Adial pharmaceuticals, inc
4
Aldeyra therapeutics, inc.
6
Alnylam pharmaceuticals, inc.
7
Amgen inc.
5
Anaptysbio, inc.
3
Apellis pharmaceuticals, inc.
4
Applied molecular transport inc.
3
Aquestive therapeutics, inc.
9
Arcutis biotherapeutics, inc.
4
Argenx se
5
Astellas pharma inc
10
Avalo therapeutics inc
3
Bausch health companies inc.
3
Beigene, ltd.
8
Biogen inc.
6
Biontech se
4
Brickell biotech, inc.
3
Bristol-myers squibb company
5
Can-fite biopharma ltd
3
Clene inc
7
Connect biopharma holdings ltd - adr
3
Crinetics pharmaceuticals, inc.
4
Cybin inc
4
Cytokinetics, incorporated
5
Dare bioscience, inc.
5
Eli lilly and company
8
Envveno medical corporation
5
Fibrogen, inc
6
Fortress biotech, inc.
6
Galecto, inc.
4
Genmab a/s
4
Icosavax inc
4
Inflarx n.v.
4
Ionis pharmaceuticals, inc.
8
Johnson & johnson
9
Journey medical corp
5
Lianbio - adr
4
Madrigal pharmaceuticals, inc.
5
Mereo biopharma group plc
4
Mind medicine inc (sub voting)
4
Neurosense therapeutics ltd.
4
Orange
4
Palisade bio inc
4
Pfizer, inc.
14
Protagonist therapeutics, inc.
4
Regulus therapeutics inc.
4
Sanofi
19
Sellas life sciences group, inc.
4
Sorrento therapeutics, inc.
4
Takeda pharmaceutical company limited
5
Tarsus pharmaceuticals, inc.
6
Tonix pharmaceuticals holding corp.
6
Travere therapeutics inc.
6
Xortx therapeutics inc.
4
Symbols
BHVN
1
BNTX
3
FNCTF
1
PFE
14
SNY
3
SNYNF
1
Exchanges
Nasdaq
4
Nyse
14
Crawled Date
2023 - 12 - 01
1
2023 - 10 - 26
1
2022 - 10 - 04
1
2022 - 03 - 30
2
2022 - 03 - 29
1
2022 - 03 - 23
1
2022 - 02 - 14
1
2022 - 01 - 12
1
2021 - 09 - 29
1
2021 - 08 - 30
1
2021 - 08 - 04
1
2021 - 04 - 01
1
2021 - 03 - 31
1
Crawled Time
01:00
2
11:00
6
12:00
3
12:30
2
22:00
1
Source
www.biospace.com
10
www.globenewswire.com
3
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Topline
entities :
Pfizer, inc.
save search
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Published:
2023-12-01
(Crawled : 22:00)
- biospace.com/
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-15.69%
|
O:
-4.92%
H:
1.48%
C:
-0.21%
obesity
topline
results
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Published:
2023-10-26
(Crawled : 11:00)
- globenewswire.com
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-16.4%
|
O:
-0.39%
H:
2.48%
C:
1.8%
SNY
|
$46.24
0.96%
1.2M
|
Health Technology
|
-13.6%
|
O:
0.09%
H:
0.0%
C:
0.0%
BNTX
|
$86.57
0.27%
1M
|
Health Technology
|
-9.35%
|
O:
0.99%
H:
1.81%
C:
0.47%
covid-19
vaccine
positive
influenza
topline
program
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
Published:
2022-10-04
(Crawled : 11:00)
- biospace.com/
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-41.8%
|
O:
0.25%
H:
1.33%
C:
0.47%
topline
trial
positive
results
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published:
2022-03-29
(Crawled : 01:00)
- biospace.com/
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-51.78%
|
O:
1.35%
H:
0.15%
C:
-2.33%
trial
potential
positive
results
topline
license
phase 3
ulcerative colitis
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published:
2022-03-30
(Crawled : 01:00)
- prnewswire.com
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-51.29%
|
O:
0.87%
H:
0.98%
C:
-1.43%
trial
potential
positive
results
topline
license
phase 3
ulcerative colitis
Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential
Published:
2022-03-29
(Crawled : 11:00)
- biospace.com/
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-51.78%
|
O:
1.35%
H:
0.15%
C:
-2.33%
trial
potential
positive
results
phase 3
topline
ulcerative colitis
Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients
Published:
2022-03-23
(Crawled : 12:00)
- biospace.com/
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-52.57%
|
O:
-1.94%
H:
0.0%
C:
0.0%
trial
positive
results
phase 3
topline
ulcerative colitis
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Published:
2022-02-14
(Crawled : 12:30)
- biospace.com/
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-49.41%
|
O:
-1.89%
H:
1.36%
C:
-0.04%
BHVN
|
$44.82
2.4%
510K
|
Health Technology
|
-67.54%
|
O:
0.27%
H:
2.86%
C:
1.95%
treatment
trial
migraine
china
topline results
positive
results
topline
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
Published:
2022-01-12
(Crawled : 12:30)
- biospace.com/
FNCTF
|
$11.0354
320
|
Communications
|
0.6%
|
O:
0.0%
H:
0.0%
C:
0.0%
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-54.76%
|
O:
-0.77%
H:
1.46%
C:
0.55%
phase 3
topline
order
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
Published:
2021-09-29
(Crawled : 12:00)
- biospace.com/
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-40.31%
|
O:
0.42%
H:
1.09%
C:
0.72%
positive
results
vaccine
phase 3
topline
order
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
Published:
2021-08-30
(Crawled : 11:00)
- biospace.com/
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-45.77%
|
O:
-2.47%
H:
2.08%
C:
1.21%
positive
results
dermatitis
phase 3
trial
topline
atopic dermatitis
Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata
Published:
2021-08-04
(Crawled : 12:00)
- biospace.com/
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-43.76%
|
O:
-0.72%
H:
0.99%
C:
-0.35%
phase 2
positive
results
phase 2b
trial
topline
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
Published:
2021-04-01
(Crawled : 11:00)
- globenewswire.com
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-29.09%
|
O:
0.19%
H:
0.41%
C:
0.0%
SNY
|
$46.24
0.96%
1.2M
|
Health Technology
|
-7.26%
|
O:
-0.22%
H:
0.51%
C:
0.02%
BNTX
|
$86.57
0.27%
1M
|
Health Technology
|
-20.93%
|
O:
1.21%
H:
3.23%
C:
3.04%
covid
topline
vaccine
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
Published:
2021-03-31
(Crawled : 11:00)
- globenewswire.com
PFE
A
|
$25.475
-0.84%
35M
|
Health Technology
|
-28.86%
|
O:
0.11%
H:
0.77%
C:
0.22%
SNY
|
$46.24
0.96%
1.2M
|
Health Technology
|
-6.6%
|
O:
0.59%
H:
0.36%
C:
0.12%
BNTX
|
$86.57
0.27%
1M
|
Health Technology
|
-17.33%
|
O:
4.81%
H:
1.4%
C:
-0.25%
covid
positive
results
topline
vaccine
covid-19
Gainers vs Losers
63%
37%
Top 10 Gainers
INVO
|
$2.78
265.79%
200M
|
Health Technology
EDBL
|
$7.4
62.64%
12M
|
RYDE
|
$3.89
42.49%
1.2M
|
n/a
GRTX
|
$0.237
39.41%
13M
|
Health Technology
VNDA
|
$5.28
30.37%
21M
|
Health Technology
VIRX
|
$0.912
27.59%
170K
|
Manufacturing
WISA
4
|
$7.72
26.56%
51M
|
Electronic Technology
LUXH
|
$1.045
26.06%
540K
|
RCAT
|
$1.41
25.89%
3.2M
|
Information
TCON
|
$2.135
24.85%
440K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.